A fresh Ebola flare‑up in the Democratic Republic of Congo and Uganda has killed more than 80 people and infected hundreds, prompting the World Health Organization to convene an advisory panel on Tuesday. The group will rank candidate jabs for fast‑track clinical trials, a test of global readiness after past response failures and underscore the urgency of securing a commercial vaccine pipeline today.

The Coalition for Epidemic Preparedness Innovations (CEPI) will feed the WHO panel data from its own analysis of research teams tackling the Bundibugyo virus. Lurie, CEPI’s preparedness chief, framed the effort as a proof point for the 100‑day mission to deliver pandemic vaccines, even as donor cuts threaten financing for such rapid‑development platforms. The analysis also maps manufacturing capacity gaps worldwide.

DR Congo and Uganda will decide which WHO‑endorsed candidates move to trial, weighing community acceptance and ethical safeguards. CEPI hopes to announce partner commitments soon, though timelines remain vague. For investors, the scramble spotlights demand for AI‑driven drug‑discovery firms and vaccine manufacturers, while funding shortfalls could pressure pricing and profit margins in the emerging pathogen market.